Vyne Therapeutics Inc. has selected a development candidate, VYN-202, for its oral BD2-selective bromodomain and extra-terminal (BET) inhibitor program for the treatment of immuno-inflammatory ...
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results